Merck KGaA (MRK) Earnings Call Transcript & Summary

May 12, 2021

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 76 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and welcome to the Merck Quarter 2021 Analyst Telco Conference Call. This call is being recorded today. Right now, I'd like to hand things over to Constantin Fest. Please go ahead.

Constantin Fest

executive
#2

Good day, everyone, and a very warm welcome from my side. I'm Constantin Fest, and I serve as head of Investor Relations at Merck. It's a pleasure to have joining me today, both for the presentation and for the Q&A, Belén Garijo, CEO of the Merck Group, along with Marcus Kuhnert, CFO of the Group. For the Q&A portion of this call, Peter Guenter, CEO of Health Care, and Kai Beckmann, CEO of Electronics, will also be on hand to answer all questions concerning Health Care and Electronics. Matthias Heinzel, our new CEO of Life Science, will join this call for a brief introduction, while Andrew Bulpin, who is in charge of Life Science process solutions, will be available for your detailed questions on Life Science and Process Solutions in particular.

Belén Garijo

executive
#3

Thank you, Constantin, and a very warm welcome to everyone. Before we get into the specifics of the quarter, I'd like to offer a few general comments. First, let me say that it is a genuine pleasure and a great honor to be with you on my first earnings call as Merck's CEO. I'm truly excited to take the company forward. And needless to say, my aim is to secure an even more successful future for Merck. At Merck we hold a strong vision that all of our leaders broadly share and, of course, so does the company's executive board. It is to accelerate our leadership in science and technology across every one of our sectors, to globalize our business further still and to mobilize for growth everywhere. In the weeks ahead, alongside my colleagues on the executive board and our global teams, we will flesh out and finalize our study and get ready to take important decisions, beginning with capital allocation decisions, so as to ensure long term profitable growth and sustainable value creation. From the several meetings I've held with many of you lately, I am keenly aware of your interest in learning more about our plans and our priorities.

Belén Garijo

executive
#4

Our whole capital markets day in September will be devoted to sharing these plans and discussing them with all of you. Your feedback matters a great deal to us. And I firmly believe that both sides gain when we deepen our ties with the capital markets, keeping up a spirit of transparency, clarity and genuinely honest dialogue. In that connection, I want to make two points. First, on my pharma background — a question I get often — you can count on me to be a business champion for all three of our sectors. Since joining the Executive board in 2015, I have been closely involved in shaping the group's transformation agenda, which gave me the chance to tackle the strategic challenges and the strengths across all our businesses. Second, I believe in substantive debate over content, best led by the respective business owners, and so from now on I will be present at every quarterly recall, joined by all my colleagues on the executive board. That way you will have the chance to hear information first-hand from our business leaders.

Marcus Kuhnert

executive
#5

Thanks, Belén, and hello from me as well. Turning now to slide nine, where we begin with a summary of the key numbers for Q1. As Belén said, the results reflect a really strong start to the year. Even with substantial currency headwinds, group net sales were up 6% to €4.63 billion, EBITDA pre climbed 28%, and EPS pre rose 45% versus Q1 2020. Financial results and tax rates both improved markedly, and I'll go into that in more detail shortly. Operating cash flow more than doubled, reaching €1.2 billion, helped by some working capital management as well as some phasing. Net debt came down by roughly €700 million versus the year in 2020, and the ratio of net debt to EBITDA pre improved sequentially from €2.1 to €1.8. On slide 10, a few remarks about our reported earnings: EBIT rose €327 million year-on-year, in line with EBITDA pre. Financial results improved considerably thanks to refinancing benefits, progress in deleveraging the group, and lower LTIP provisions. The effective tax rate was 24%, in line with our new guidance range of 22% to 24%.

Marcus Kuhnert

executive
#6

So as a result, earnings per share climbed 63.8% to €1.72, up from €1.05 a year earlier. Just keep in mind that we anticipate additional downward pressure on effective tax rates over the next few months. And then higher shelf profits are going to be booked in jurisdictions with lower taxes. That also means that starting in Q1, the underlying tax rate used when calculating EPS pre will be 23% — we will, though, going forward, watch any shifts in tax regulations carefully and closely, since those effects aren't reflected here.

Belén Garijo

executive
#7

Thanks, Marcus. I'm on slide 17 now. I'll begin with a quick update on ESP. You've already heard about the new sustainability targets we launched at the end of 2020. We want to reassure you that this topic matters enormously to me, and I'm convinced that our integrated sustainability approach will help Merck and our businesses perform even better. In fact, we don't treat sustainability as a reporting obligation — we see it as a cornerstone of our innovation agenda. The executive board will champion this strategy, and we're very pleased that three weeks ago the Annual General Meeting approved the new executive board compensation system, which includes sustainability objectives. We're currently working on concrete measures to steer our way toward our sustainability targets and can now develop a set of key performance indicators to build the sustainability factor for the compensation system. Smart KPIs will help select the most effective initiatives to improve in the spirit of our sustainability approach. One example is the virtual power purchase agreement we signed in the first quarter with Eneel green power. These so-called VPPAs are an important component of our study toward climate neutrality in 2014.

Belén Garijo

executive
#8

This will also substantially boost the proportion of our electricity that comes from renewables. That said, let's turn to slide 18 and review what we're assuming about COVID-19 for 2021. As you'll see, the broad assumptions we shared with you in March remain essentially unchanged. Looking at it by business sector, the assumptions we hold for healthcare and electronics stand as confirmed. In the meantime, though, we've grown somewhat more optimistic—or more optimistic—regarding our life science assumptions. Our view now is that COVID-related demand in surface solutions will prove even stronger than we had earlier assumed, which translates into a better growth outlook as additional capacity becomes available. Under life science, the trends for the remaining two businesses should be somewhat more volatile, and also more varied across the different customer segments. Still, we've gotten more precise, and we now assume that COVID-related effects will be positive in research, and very limited in Applied. Turning to slide 19, I'd like to offer some additional color on the life science outlook in the context of the pandemic, since as you know, this is our primary growth engine going forward and, overall, as a business devoted to making infinity solutions possible—so, as our new life science CEO puts it, we translate our purpose into action in the fight against COVID-19 through accelerated innovation and increased investment.

Belén Garijo

executive
#9

After the headwinds caused by the first lockdowns in spring of last year, we've witnessed considerable acceleration in growth, driven by recovery in the underlying business and a growing tailwind from COVID-related businesses. As I said earlier, roughly half of the growth in life science since Q2 of last year can be credited to product leverage in COVID—in COVID vaccines. COVID therapies and COVID diagnostics lean toward process solutions, followed by research, with minimal effects in our applied business. Demand in substantial portions of our portfolio has been genuinely unprecedented. And given that, we've moved with agility and a great deal of decisiveness to tackle bottlenecks where needed. Over the past 12 months on its own, with more than €380 million invested in finance in total, and we keep making excellent headway when it comes to raising output from our current plants and ramping up new production sites. Most recently, we managed to speed up even further some very important initiatives—specifically the one for single-use assemblies involving numbers and motion, and the one for filtration involving our Jaffray site. Strong demand will be there across both core and COVID-related business. That is also among the chief reasons behind the guidance we applied for life science.

Belén Garijo

executive
#10

We now anticipate that our life science sales tied to COVID will greater than double during 2021 versus 2020, and that COVID-related sales in process solutions will rise by a factor of no less than 2.5 times. As you’re aware, the overall situation continues to be highly dynamic, and it’s hard to speculate about how large and how lasting COVID-related demand will be over the medium term, though I’ll be glad to take questions on that later. That said, we anticipate that a potential need for vaccine and therapy approaches will get underway this year. As a result, we expect at least €500 million in COVID-related process solution sales by 2022. At the same time, core business momentum is still very encouraging, and we keep reviewing long-term demand for the products in our portfolio against the capacity we expect to have, so that we can respond appropriately. Turning to the next slide, I’ll give a quick update on Mavenclad in the context of COVID-19. Mavenclad is a key strategic growth driver for Merck, and although Q1 performance was somewhat muted because of the challenging market conditions we described earlier, we stay confident about Mavenclad’s outlook. 2.8 million people living with MS around the world have begun, and will keep receiving, COVID-19 vaccination in the weeks and months ahead.

Belén Garijo

executive
#11

We think every one of these patients, no matter what background therapy they're on, needs reassurance that vaccination will genuinely work and produce immunity. So in this new vaccination era, one of the most urgent questions we're getting from the MS community is whether COVID-19 vaccines will work for patients receiving certain types of MN therapies. What you're looking at is actually the first ever published real gold study done by independent investigators in Israel. And we think it shows how Mavenclad differs from other high efficacy therapies in this very challenging setting of rising vaccinations. The data speak for themselves: the study showed that all Mavenclad treated patients who received an mRNA COVID-19 vaccine could mount a full antibody response similar to that of affected people. This seems to stand in stark contrast to the other two high efficacy drugs, for which protective humoral immunity was significantly lower. And we think these data are great news for the MS community and also a chance to uniquely position Mavenclad for future growth. With that, let's take a closer look at our upgraded guidance on slide number 21. As you'll see there, we expect growth next sales in 2021 in the range of €18.5 billion to €19.5 billion.

Belén Garijo

executive
#12

EBITDA pre margins somewhere between €5.4 billion and €5.8 billion, with earnings per share pre coming in at €7.5 to €8.2. That rests on organic sales growth of 10% to 12%. Organic EBITDA pre growth, adjusted for the Biogen commission reversal, lands in a range of 16% to 20%. That's significantly better than what we anticipated at the start of the year, driven by an improved demand outlook — and importantly, paired with our continued focus on cost discipline. FX should be a headwind of roughly 2% to 4% on both sales and EBITDA pre, so slightly less than what we communicated to you in March. For the outlook details by business sector, let's take a quick look at slide number 22. Briefly, to summarize, we expect group sales and EBITDA pre growth to be supported by all three business sectors, with life science expected to grow fastest, followed by healthcare and electronics, relative to our qualitative outlook from March. And as already mentioned, we've become more positive for all sectors, although life science clearly stands out. With that, and before opening the Q&A, it is with great pleasure that I hand it over to Matthias Heinzel, who joined us April 1 as our new CEO for Life Science, for a few introductory remarks.

Belén Garijo

executive
#13

Matthias, the floor is yours.

Matthias Heinzel

executive
#14

Yes, thank you so much, Belén, and hello everyone joining today's call. To start, I want to express real gratitude for the warm reception I've gotten from my new colleagues around the world. Since a lot of you listening probably aren't familiar with me or my background in this sector, I'll take a moment to introduce myself briefly. I'm Matthias Heinzel, as Belén said, and I became CEO of Life Science for Merck only a few weeks back. Before this, I was at DuPont, where I worked for the last 18 years, taking on a range of senior business leadership positions and based in different places, including Germany, Denmark and the United States. Right before joining here, I was a member of the Executive Board and President of the Nutrition and Bioscience Business. Earlier still, back in the early 90s, I held several leadership positions spanning marketing, strategy and business development in the telecoms industry. And my career actually began at McKinsey. So from my perspective, there's truly no better moment than now to come on board at Merck. I'm genuinely thrilled to be leading Life Science. It's a fantastic business, as today's results demonstrate, and it operates so successfully in such a highly attractive market.

Matthias Heinzel

executive
#15

Life Science’s impressive capabilities, its wider deep portfolio, and its massive worldwide footprint give us an excellent basis for generating profitable growth in the future for the business, which benefits our customers, shareholders and employees. And clearly, the COVID-19 pandemic is merely one illustration of the beneficial difference we can achieve and the essential part we perform. I’ve already had the chance to connect with a large number of my new colleagues. I have in fact already done many virtual side visits and gotten involved in a lot of the crucial subjects. So I’m genuinely eager to get acquainted with you, our investors and analysts, and to take part actively in conversations with you, particularly once I have finished my first 100 days. With that being said, I’m truly enthusiastic about collaborating with Belén and my executive team colleagues to elevate an already excellent business to the next level. And on that note, over to you, Constantin.

Constantin Fest

executive
#16

Thanks, Matthias. Keane, can we take the first question, please?

Operator

operator
#17

All right. Our first question now comes from Richard Vosser at JPMorgan.

Richard Vosser

analyst
#18

Hello, and thank you for taking my question. My first question is for Belén, please. Belén, I understand you said the capital markets day is going to focus on a strategy update. But I was hoping you might share some of your initial thinking on how you view Merck's strategy — are there areas that require a change of focus or a different emphasis, or parts of the group that, in your opinion, need strengthening or have become less relevant, based on this first look you've taken across the group in your new role? And then my second question, please, is just on Mavenclad. The quarter was, I think, weaker than expected? Is there any price pressure in the U.S. or Europe, and you said you were confident, but how would you bridge the gap from here, with annual sales of €600 million, to the €1 billion to €1.1 billion? Thanks very much.

Belén Garijo

executive
#19

Thanks, Richard. As was noted, for the detailed information, we'll be together for a whole day in early September, and that's coming up soon. But let me give you the three principles. First, continuity. We're beginning this journey from a really solid position of strength. Second, focus. A stringent focus on the three big and maintaining our cost discipline so we deliver sustainable and profitable growth for our business. Last but not least, obviously, as our cash position gets better, we'll be thinking about how we strengthen our outlook by eventually considering a better balance between inorganic efforts across the 60 sectors and eventually, and a stream of sales approach beginning in 2022. More to come in September.

Peter Guenter

executive
#20

And Richard, this is Peter here. Thanks for asking about Mavenclad. So, clearly, at the moment there's no pricing pressure, neither in Europe nor in the U.S. So the somewhat depressed sales in Q1 stem entirely from the depression of the high efficacy markets. There's absolutely no performance problem — we keep gaining share in the high efficacy market, in both the U.S. and Europe. And we're confident that, as lockdowns decrease thanks to rising vaccinations, this high efficacy market will progressively return to its normal levels as the year unfolds. Finally, I think Belén already mentioned that, of course, the vaccination data are absolutely key. They're extremely relevant for neurologists and for patients at large. And, and we do believe that it would put us in a unique position to further drive up our market share over the rest of the year.

Richard Vosser

analyst
#21

I really appreciate it.

Operator

operator
#22

Our next question now comes from Matthew Weston at Credit Suisse.

Matthew Weston

analyst
#23

Thank you. I have two questions, please. The first one concerns Life Science. I'm a little puzzled by the outperformance in research. Over the last nine months, COVID diagnostics has clearly been a very significant driver, and that hasn't materially affected that business. So I would be quite interested to hear why that is now a factor in 1Q. I'd also like to understand the trends in non-COVID bio process revenue. Is there any sign that your customers are stockpiling ordinary orders, so that in essence revenue has been pulled forward? And will that have to correct at some point, when everything returns to a more normal supply chain after COVID? Then secondly, a finance question for Marcus. I know you've reduced the tax guidance on core. And I fully understand that this is driven by the mix toward Life Science. But given that we're in a period with exceptional Life Science income, and also a number of governments are pointing toward higher corporation tax in the future, I'd be very interested to understand what you've baked into those tax assumptions for the midterm. Is that something specifically for 2021, or something we should take as a useful guide going forward?

Matthew Weston

analyst
#24

Thanks.

Belén Garijo

executive
#25

Thanks, Matthew. I’ll begin with research, and then I’ll have Andrew pick up on process. So research is strong, correct? Research is strong when you look at two things: first, low comparables relative to last year; second, a bit of a catch-up effect coming from activity restarting, primarily in pharma and biotech. So we’ve observed ongoing business recovery throughout every business line, every region, and every customer as that prior lab activity keeps improving. It will carry into the future — I already said this in our brief remarks during the outlook — we are not expecting that. So bear in mind that in the first half of the year, comparables will be very tough, because Q2 versus Q2 2020 was also a hard one tied to COVID. So we expect the second half of the year won’t behave precisely according to the standards we saw in Q1. That’s the bottom line. Then, on process, I said, Andrew, would you like to comment on Matthew’s question, please?

Andrew Bulpin

executive
#26

Of course, no problem at all. Hello, Matthew — trust you're doing well, and thank you for asking. On whether we think our customers are building up stockpiles: definitely not. Throughout this pandemic period, we've collaborated extremely closely with every one of our customers. One of the major difficulties, I'd say, comes from surge demand, and in a lot of instances where supply is constrained, it's genuinely hand to mouth. That's why we've coordinated very closely with all our major accounts to make sure they receive what they require, delivered as best we can whenever they need it. Still, we've had to manage that inventory and the flow of materials given the demand surge. Broadly speaking, regarding the base business versus COVID-19, the split last year came to roughly 50:50. In quarter one this year it looks similar, so the base business is very strong. There's simply a great deal of activity across the industry right now; the traditional modalities, the maps, stay very, very strong. And with all the novel modalities, opportunities exist, since they target diseases and conditions that historically couldn't be treated — so the market is robust at present, with a very good tailwind coming from COVID-19.

Marcus Kuhnert

executive
#27

Matthew, I'll address your question about the tax rate, of course. So to begin with, let me just confirm again that you're absolutely correct — the primary factor behind the lowered effective tax rate guidance for 2021 was in fact a shift in the country mix where our pre-tax profits are located, and that's clearly mostly the result of the strong growth momentum in Life Science, where more gains are arising, for instance, in the U.S., which right now is a country with a tax rate below the average. From that, we can right away conclude that for the foreseeable future — for the near term — we'll keep seeing downward pressure on the tax rate, since we believe, as Belén also outlined in the presentation, that next year as well we would still get at least 500 million in additional COVID-19 related sales. And that will obviously bring similar downward pressure to what we've seen this year. Your second assumption, Matthew, was also correct. At the moment we see a great deal of uncertainty concerning how tax regulations will develop in various countries going forward. That's obviously connected to the fact that nations are now considering how to absorb the economic consequences of the COVID crisis.

Marcus Kuhnert

executive
#28

And we think tax rate adjustments are probably going to arrive in a lot of cases. Please keep in mind that at this point, in May, providing a longer-term projection is simply premature. So that's why we're comfortable stating that for the moment, the lower rate of 22% to 24% applies only to 2021. But you can be sure we'll bring you a further update as this year goes on—say, on what's happening on the tax regulation front and how that could affect the rate as we move into 2022. One final sentence to wrap up. And the way I see things right now, there's just one thing—a single event—that could, I'd say, really alter the picture in a significant way. That would be a major U.S. tax reform. It's something under contemplation and consideration, but it remains at a very infant stage. And as I mentioned, we'll keep you updated as the year unfolds.

Matthew Weston

analyst
#29

Much appreciated.

Operator

operator
#30

Our next question comes from Peter Verdult at Citi.

Analyst

analyst
#31

Yes, hello there. Am I coming through okay?

Belén Garijo

executive
#32

Yes.

Vineet Agrawal

analyst
#33

Yes, hello, Vineet speaking on Peter's behalf. We have two questions. The first concerns electronics. Could you address the current rise in chip demand and how that compares with your 6% to 8% growth target for semi solutions? Should the double digit growth scenario be considered for both 2021 and 2022? And the second question is on Life Science: we appreciate that the 37% margin you reported in 1Q is unsustainable. But likewise, the 32% to 33% range you previously guided to also appears too conservative. Now, given the mix change we have seen within the Life Sciences business, what is the sensible level of profitability to assume going forward? Thank you.

Marcus Kuhnert

executive
#34

I'll start us off. Thank you for that question. You were asking about the close expectation and how it ties to the Q1 situation — just keep in mind that our Q1, of course, is being compared against a very fine Q1 last year. Also, our delivery systems and services business isn't as steady as the material business. That's what we see: quite a few jumps from quarter to quarter. If I could point you to slide number 37 in the backup, you'll see organic growth listed quarter by quarter there. And it shows a steady, steady situation overall across the past five quarters. That's why, at the outlook, we're confident looking forward to the next quarter, which is included in our guidance for 2021, with a very strong outlook that we've demonstrated here. I wouldn't want to give any outlook on 2022 right now, since the situation doesn't permit an outlook for 2022, but you know our long-term guidance materials, semi solutions being in the up to a high single digit growth, shows that we're pretty confident on the long-term trends, and our customers announcing capacity upgrades, significant capacity upgrades that may come on stream in about 18 months, that gives us additional confidence about the future in electronics.

Belén Garijo

executive
#35

I'll begin with the second question, and I'll have Marcus add to that. Looking ahead, we've said many times that we have a great deal of confidence in the growth of process solution sales. But please keep in mind that we'll also need to make investments. We have to put money into growing our Life Science business. We have to put money into R&D. We're prepared to invest in CapEx as well, even though that won't show up here. With that in mind — and we will strike the right balance and remain efficient — but assume that our intention is to keep investing in Life Science growth so that the outlook stays as promising as it is. Marcus?

Marcus Kuhnert

executive
#36

Yes, thank you, Belén. Those are, of course, what I'd call the strongest arguments. My points merely served to complement them a little, and to build on that, one additional effect worth mentioning might be this: while we believe the tailwind from process solutions will stay strong throughout the year, what our research has shown is that this first quarter was most likely quite unprecedented. And here, we might see that tailwind tapering somewhat over the quarters ahead. We will still see a very benign and positive business environment, but I doubt we'll see those growth rates going forward. Also bear in mind that, as we've said, the comparables are getting much, much tougher. As you know, a significant portion of those margin improvements is also down to positive business mixes. And when the COVID-19 related tailwind, at least in research, declines a little bit, the positive business mix effect will decline as well. Still, our guidance entails, if you take the midpoint in sales and EBITDA, a 260 basis points increase in margin, which would lift the margin from 32% at the end of last year to a level of close to 35% in 2021.

Marcus Kuhnert

executive
#37

And I'd call that a pretty nice expansion in margin.

Constantin Fest

executive
#38

Let's take the next question.

Operator

operator
#39

Our next question now comes from Sachin Jain at Bank of America.

Sachin Jain

analyst
#40

Hi, thanks for taking my questions. I had a couple more on Life Sciences if I may. And kicking off with process solutions. Firstly, for the quarter I think process growth had 30% organic compares to peers in the high 50s. So when you just do a compare and contrast and give us any color on the performance there in terms of capacity constraints or your order book delivery timelines potentially being longer. Secondly, Belén in your introductory comments. I think you mentioned process COVID sales of €100 million by 2022. I just wanted to clarify whether that was delivered in calendar year 2021. Or that was a comment for 2021 and 2022. And if it was the latter, if you could give us any color on the splits across the years. And then I guess that's a wrap the question I guess the simple question that I get asked is, you'd be very clear on sustainability of COVID tail winds into 2022. I guess the question is, is the COVID tail wind in 2022 the same, greater or less than the tailwind in 2021? Thank you.

Belén Garijo

executive
#41

Thanks, Sachin. First, I’ll turn it over to Andrew to talk about the Life Science order book. Andrew, could you address that and give us a little more detail, please?

Andrew Bulpin

executive
#42

Sure, absolutely. I think there are a few things here. First, I think your analysis is right that turning orders into actual sales really hinges on having short-term capacity available. And then we certainly do have some pinch points. But I think some of what we're seeing is that the quick decisions we made last year to speed up capital investments are beginning to pay off — they came on stream in early January. And we've seen output tick up, as the numbers for this year demonstrate. And we will keep ramping up throughout this year. We also announced an investment, for example, in Danvers, which is our single use that's now on stream in Jaffray for our filtration products, that's now on stream, and we're feeling the benefits. But also looking at it geographically, an investment in the single use facility in the Strasbourg area on our multi campus, which I think gives us a little bit extra sort of protection from geodiversity, then having a more global network moving forward. So it's, it's definitely moving in the right direction. The order intake and the order book remain strong. And we look forward to being able to deliver upon those, as the capacity ramps up in these new investments.

Belén Garijo

executive
#43

Sachin, regarding your second and third questions about the COVID-19 tailwind, let me address those. Again, how large and how lasting COVID-related demand will be is somewhat hard to gauge over the medium term, because there is uncertainty about the durability of the approaches currently in use, along with the possible effects of nuisance. That said, we believe there is a reasonable chance the COVID-19 pandemic could become pandemic, which would point to potential need for boosters. As a result, demand for vaccine and therapy approaches will exist during the current year. That is our global view as we capture our assumptions. As I shared with you previously, for 2021 and beyond, this reflects the outlook we hold for the years ahead. Given the disability we have at present, what I indicated during the presentation is that we expect at least 500 million in COVID-related sales for our process solution business in 2022.

Sachin Jain

analyst
#44

Thanks.

Andrew Bulpin

executive
#45

Perhaps I could just tack on one more remark there. If you look at the kind of profile, say, of the booster shots versus the initial vaccination programs, in some conversations with the major manufacturers, these actually use a different formulation, and they may hold a smaller amount of active ingredient than the original vaccination shot. So just as a caution, when you hear something like 1 billion doses in 2021 becoming 3 billion doses next year, that doesn't automatically mean a 3x rise at the business level.

Sachin Jain

analyst
#46

Could I just ask a quick follow-up regarding that 500 million you mentioned for 2022? What does your guidance imply for 2021? It appears to be roughly €700 million. And what did that figure come to in 2020? Once more, it seems to be around €200 million. I was hoping you could clarify those figures for us so we can get the sequencing right across the years. Thank you.

Belén Garijo

executive
#47

Yeah, Marcus will take that one.

Marcus Kuhnert

executive
#48

Right, Sachin, I believe that 2020 figure came in at roughly 400 million. Our projection for the sector puts it at a minimum of 2 for 2021. That would suggest we finish this year near 900 million, in all likelihood, with total COVID tailwinds, and most of that is clearly taking place in process solutions. Then for 2022, as Belén just described, something beyond 500 million.

Sachin Jain

analyst
#49

That’s great. Thanks a lot.

Operator

operator
#50

The following question comes from

Krishna Arikatla

analyst
#51

Hi everyone, thanks for taking my questions. I have two, please. The first is on Mavenclad — I'm just trying to get a better handle on the softness there. Can you give us any detail? Is that softness coming from fewer patients moving into the second year of treatment? Or is it being driven by fewer patients that please? That's the first one. The second is on COVID demand in the quarter in Life Sciences. Is that mainly being driven by COVID vaccines? Or is there a decent chunk from COVID antibody treatments as well, please? Thank you.

Belén Garijo

executive
#52

Casey, I’ll take the first question really quickly. The bulk of it comes from vaccines, with a smaller share from diagnostics and therapeutics — almost very, very small — vaccines? Peter, you might…

Peter Guenter

executive
#53

Casey, thanks for the question. So you actually have two effects here. First, the lockdowns, and the absence of—there’s a clear link between mobility and new patient starts. Okay. So essentially, most of the drop in the high efficacy market comes from fewer patient starts. And there’s some effect on year two patients, because remember, in March of last year, we began seeing an impact on new patients during the first COVID wave—meaning you also get some effect on the year two returns for that patient, since someone who was supposed to be treated in March last year was not treated and so also did not come back this March. But I’d say most of the impact would be on new patient status. And by the way, we see it on both sides of the…

Analyst

analyst
#54

Thanks.

Operator

operator
#55

Our following question now comes from Parker Friedrich at Deutsche Bank.

Parker Friedrich

unknown
#56

Thanks a lot. Good afternoon. My first question goes back to that €500 million of COVID revenue in 2022. Thanks for giving us that figure. Did I get it right that this applies solely to the process solution side of the business? Or does it also cover possible COVID revenue within the research solutions business? Or would the research solutions business come on top of the €500 million? And then second, regarding the continuing semiconductor shortage, could you perhaps say a little more about how this situation should impact your business across the year and to what degree your electronics business might benefit from it?

Belén Garijo

executive
#57

Thanks, Parker. To make your first question clearer — that figure represents the floor, and it applies to our process solution business.

Peter Guenter

executive
#58

I’ll address the semiconductor part of the question. This shortage, naturally, indicates that our customers are operating at full steam and high utilization right now. That, of course, means there is some ceiling on existing capacity. Yet over the past month—during the last month—our customers have been announcing capacity additions, and that gives us very strong confidence regarding the future outlook for semiconductor production capacity, which is essentially our target market. As for the present situation, the shortage will persist until new capacity comes on screen. And that may not be much sooner than what I mentioned earlier in the question: 18 months from now. That is the situation we are in, but at present there is full utilization across all the different areas in semiconductors.

Parker Friedrich

unknown
#59

Alright, thanks.

Operator

operator
#60

Our next question now comes from James Quigley at Morgan Stanley.

James Quigley

analyst
#61

Hi folks, thanks for taking my questions. I actually have a couple of questions. So on Mavenclad, I'm not sure whether I missed this in the release, but could you give us a sense of what the split is between the U.S. and ex U.S.? And then regarding the interesting data on slide 20, which says the T cell response is still maintained in patients and offer infection in patients who have up reverse and the COVID vaccine, then we will look at the infection rates in the Phase 3 trials with CD-20 that they're not significantly elevated. I mean, do you have any other evidence or real world real world data suggesting that patients on CD-20 therapies are more susceptible to COVID-19 infection, in which case the data you presented could be very, very powerful. And then also sort of on MS, could you give us an idea of what the exit rate related latest data at least in the last month at you have shown for the high efficacy market trends in the U.S. it is to sort of get a sense of the opportunity here from having played in, in that in that area.

James Quigley

analyst
#62

Moving to the second question about fertility dynamics. What trends are you observing in the various regions, and where do things stand regarding fertility clinics reopening? Are we roughly near a reopening of 2 to 4 in the U.S. and APAC, the areas where you noted especially strong signals? Or might there be additional developments ahead for..?

Belén Garijo

executive
#63

Peter, go ahead.

Peter Guenter

executive
#64

Yes, so, many thanks for those questions, James. First off, the ex-U.S. versus U.S. split sits at roughly 50:50. It shifts somewhat from quarter to quarter, but approximately, that's the figure to keep in mind, okay. On the entire debate regarding V cells and T cells, humoral and cellular immunity, what I'd say is that we clearly have very strong data showing we do generate a humoral response with very strong antibodies, really identical to normal subjects. And you observe very, very different data coming from the other high efficacy products. Now, regarding the whole debate about T cell immunity, I wouldn't venture into that space. I believe the burden of proof rests with the other high secrecy products. And I think they have some work to do to demonstrate in these that a cellular immune response would be mounted. As for market share trends in the U.S., so in the highest frequency market, if you look at the latest dynamic share points, we were at roughly between, I'd say, 5% to 6% in the dynamic, and we're at approximately 2.5% in the total market, going up. We have a somewhat different situation in most European countries, where we hold an average higher share of around 10% plus.

Peter Guenter

executive
#65

Turning to fertility, we’re extremely enthusiastic about what we’re seeing in that market. It’s genuinely a great space for us to be in. There are durable tailwinds on the demographic side. Clearly, competition there is comparatively low and weak. And after the Q2 dip, you actually saw those markets return to a normal situation fairly quickly. At this point we’re even in something of a catch-up mode, which partly explains the quite stellar Q1 results. Of course, don’t forget that in Q2 of last year we saw a pretty dramatic COVID impact and the confinements, so expect a very weak comp in the quarter ahead.

James Quigley

analyst
#66

Thanks a lot — that's great.

Peter Guenter

executive
#67

Thanks.

Operator

operator
#68

Our following question now comes from Simon Baker at Redburn.

Simon Baker

analyst
#69

Thanks for taking my questions. There are two, please. First, on Display Solutions. In the slides, you mentioned that OLED isn't yet offsetting the weakness in LCD? I was wondering whether you could tell us when you expect that to happen, and how far away we are from OLED making up for LCD declines? Then second, Marcus, this is a small point, but I just wanted to check on healthcare. There has been a bit of a shift in the amount of amortization of intangible assets within cost of goods and marketing and selling expenses. One is significantly higher than last year and one is significantly lower. I just wondered if Q1 is a good trend for the year and whether there have been any accounting policy changes. Thanks so much.

Belén Garijo

executive
#70

Kai, go ahead and ask the first question.

Kai Beckmann

executive
#71

Simon, I’ll handle the first question. So the materials market is expected to reach roughly the same level as the liquid crystal materials market around next year. That is what the market data currently indicates, but keep in mind that our position in liquid crystal is, of course, stronger; in OLED we are now regarded as competitors and in various offices stronger than that. So some time will pass before both businesses are at that same level.

Marcus Kuhnert

executive
#72

Simon, could you go over your question once more?

Simon Baker

analyst
#73

Sure, Marcus. On healthcare, intangible asset amortization sits within cost of goods and within marketing and selling expenses. Q1 looks quite different from last year. The amortization of intangibles in COGS is significantly higher, while the amount in marketing and selling is lower. Those are relatively small numbers. I was just wondering whether Q1 is a good guide for the rest of the year, and whether any accounting changes prompted that.

Marcus Kuhnert

executive
#74

I don't know of any accounting changes of that sort. As for the run rate you should expect for the year, Simon, my suggestion is that the IR team will get back to you on that directly.

Simon Baker

analyst
#75

Thanks a lot — that’s great.

Constantin Fest

executive
#76

There's time for one more question, I believe.

Operator

operator
#77

Our last question now comes from Luisa Hector at Berenberg.

Luisa Hector

analyst
#78

Oh, hi there, and thanks for the question. So, regarding this year's outlook — we're almost at the halfway mark now, and with your order books and so on, we do have fairly good visibility. I was just wondering whether you could add anything more about what's behind the top and bottom ends of your guidance range? Is COVID uncertainty still what accounts for that spread? And then, coming back to the Life Science investment: you said a few things about capacity expansion tied to COVID. Are those investments pretty much fully operational at this point? And how should we think about investment in the core underlying business, given that you've identified additional demand this year, which is part of why your guidance went up? Thank you.

Belén Garijo

executive
#79

Hi, Luisa. I believe we've already shared as much as we can on that, you know, given the visibility we have today during the presentation. So again, looking ahead to 2021, you can treat the answers I gave for Life Science as a proxy, right? Because healthcare will proceed on the high efficacy dynamic market progression, as Peter has said repeatedly, and also the greater mobility that is in fact already reflected during our Q1 results, tied to fertility and other businesses. So as vaccination progresses, we can't expect anything other than mobility and recovery, assuming the traditional healthcare dynamics of the past. Pending — and this is a separate question, and it relates to mobility, the high efficacy, dynamic market trends. On Life Science, I noted already that we have an ongoing multiyear program to expand our Life Science capacity in support of this global and growing demand. And so far, we are truly on track. I mentioned how heavily we invested in the last month. And that came to €350 million. And it's because we believe the trend will continue, as you see each and every vaccine manufacturer has announced new commitments, speaking of new vaccine doses being produced and committed to different countries and governments, and as we see these trends persisting into the future, this has given us confidence that we are going to develop further in the business, mainly in Life Science, on the basis of our increased capacity.

Belén Garijo

executive
#80

And that's really the key factor that would separate the low rate from the high rate, along with revenues, clearly.

Operator

operator
#81

Thanks. That wrapped up the final question…

Belén Garijo

executive
#82

Someone asked about capacity. I’m not sure — Andrew, would you like to say anything, very briefly, about Life Science capacity and about the capacity for expansions beyond what I’ve already mentioned?

Andrew Bulpin

executive
#83

Okay, Belén. You brought up that €380 million figure. When you break it down, it really spans both the core business and what COVID-19 has required. To give you some examples: 140 million is going into Darmstadt for a new membrane plant. €100 million goes toward battle viral vector. Then there's 60 million in Madison for high-potent APIs and for ADCs, followed by 21 million in Darmstadt for single use, 19 million in Jaffray for filtration, 18 million in books to support our reference materials, and then the 25 million investment for single routine multi. So we're investing substantially, and on top of that there's where we stand with acquiring AmpTec in the mRNA space, in the CDMO space there. And our partnership with BioNTech to speed up liquid supply represents a significant investment in both bass and COVID-19 activity across process solutions.

Constantin Fest

executive
#84

Alright, thanks so much. With that, I’d like to turn things back over to Belén for some closing remarks on this call. Belén, the floor is yours.

Belén Garijo

executive
#85

Thanks for holding. To save time, I’ll keep this very, very short, and I’ll mainly say thank you to everybody for taking the time and for growing interest in Merck. We’re eager to meet all of you. And lots of you during the road shows that our plan kicks off today. Some of them should remember that I want you to settle that view on August 5, and we’ll be hosting our capital markets day on September 9. With that, many thanks for all your questions and for your attention, and we’ll speak soon. Bye bye.

Operator

operator
#86

That brings us to the end of today's call. Thank you all for joining us. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.